Quintiles has sold its minority interest in a joint venture it helped to create in 2006.
The company, Invidia, provides sales support for biopharmaceutical products in the Asia-Pacific region. The buyer, the Menarini Group, a privately held biopharma based in Italy, now owns Invidia in its entirety. The Zuellig Group and TLS Beta Pte. Ltd. were Invidia’s other original owners.
Terms of the deal were not disclosed.
Quintiles’ Global Commercial Solutions group, whose business is similar to that of Invidia, has 7,000 employees worldwide...